Everolimus solution, 1.0 mg/ml in acetonitrile

SKU: E0574

Category: API's & Intermediates

Synonyms: 42-O-(2-Hydroxyethyl)rapamycin , NVP-RAD001 , RAD001 , SDZRAD , Zortress , Afinitor , Certican , Votubia; 159351-69-6
CAS-Number: C₅₃H₈₃NO₁₄
Molecular Formula: 958.22
Molecular Weight

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥99% (HPLC)
Identity: IR
Appearance: Liquid
Concentration: 1.0 mg/ml in acetonitrile

Properties

Use / Stability: Stable for at least 2 years after receipt when stored at -20°C.
Handling Advice: Protect from light and moisture.
Long Term Storage: -20°C
Short Term Storage: -20°C
Shipping: AMBIENT

Transportation: Packing Group II
RIDADR: 1648 3
Signal word: Danger
Precautionary statements: P210-P305 + P351 + P338
Hazard statements: H225-H302 + H332-H319

Description: Macrolide antibiotic, inhibiting bacterial protein synthesis. Potent immunosuppressant. Binds with high affinity to the FK506 binding protein-12 (FKBP-12) to generate an immunosuppressive complex that inhibits the activation of the mammalian target of rapamycin (mTOR). More selective for the mTORC1 protein complex, with little impact on the mTORC2 complex, compared to Rapamycin. Anticancer agent. Inhibition of mTOR reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest, apoptosis and autophagy, resulting in reduction of cell proliferation, angiogenesis and glucose uptake. Inhibits tumor proliferation in vitro and in vivo. This compound can be used as a reference material.
InChi: InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-
References: (1) H.J. Schuurman, et al., Transplantation 64, 32 (1997) , (2) W. Schuler, et al., Transplantation 64, 36 (1997) , (3) P. Neuhaus, et al., Liver Transpl. 7, 473 (2001) (Review) , (4) B. Nashan, Expert Opin. Investig. Drugs. 11, 1845 (2002) (Review) , (5) I. Beuvink, et al., Cell 120, 747 (2005) , (6) J.K. Patel & J.A. Kobashigawa, Expert Opin. Pharmacother. 7, 1347 (2006) (Review) , (7) P. Smolewski, Anticancer Drugs 17, 487 (2006) (Review) , (8) K. Zitzmann, et al., Neuroendocrinology 85, 54 (2007) , (9) Z. Zeng, et al., Blood 109, 3509 (2007) , (10) R. Bianco, et al., Br. J. Cancer 98, 923 (2008) , (11) A.I. Sanchez-Fructuoso, Expert Opin. Drug Metab. Toxicol. 4, 807 (2008) (Review) , (12) H.A. Lane, et al., Clin. Cancer Res. 15, 1612 (2009) , (13) D. Lebwohl, et al., Ann. N. Y. Acad. Sci. 1291, 14 (2013) (Review) , (14) U. Saran, et al., Clin. Sci. 129, 895 (2015) (Review) , (15) Morviducci, et al., Diabetes Res. Clin. Pract. (Epub ahead of print) (2018) (Review)
InChi Key: HKVAMNSJSFKALM-QATPHWSPSA-N
Smiles: OCCO[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H](CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)OC([C@@H]3CCCCN3C(C([C@@]4(O)[C@H](C)CC[C@@H](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)O4)=O)=O)=O)CC1

Macrolide antibiotic, inhibiting bacterial protein synthesis. Potent immunosuppressant. Binds with high affinity to the FK506 binding protein-12 (FKBP-12) to generate an immunosuppressive complex that inhibits the activation of the mammalian target of rapamycin (mTOR). More selective for the mTORC1 protein complex, with little impact on the mTORC2 complex, compared to Rapamycin. Anticancer agent. Inhibition of mTOR reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest, apoptosis and autophagy, resulting in reduction of cell proliferation, angiogenesis and glucose uptake. Inhibits tumor proliferation in vitro and in vivo. This compound can be used as a reference material.

SKU: E0574 Category: API's & Intermediates

Additional information

Additional information

Synonyms	42-O-(2-Hydroxyethyl)rapamycin, NVP-RAD001, RAD001, SDZRAD, Zortress, Afinitor, Certican, Votubia
Purity	≥99% (HPLC)
Appearance	Liquid
CAS-Number	159351-69-6
Molecular Formula	C53H83NO14
Molecular Weight	958.22
Identity	IR
Smiles	OCCO[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H](CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)OC([C@@H]3CCCCN3C(C([C@@]4(O)[C@H](C)CC[C@@H](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)O4)=O)=O)=O)CC1
InChi Key	HKVAMNSJSFKALM-QATPHWSPSA-N
Shipping	AMBIENT
Short Term Storage	-20°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at -20°C.
Hazard statements	H225-H302 + H332-H319
Precautionary statements	P210-P305 + P351 + P338
Signal word	Danger
RIDADR	1648 3
Transportation	Packing Group II
References	(1) H.J. Schuurman, et al., Transplantation 64, 32 (1997), (2) W. Schuler, et al., Transplantation 64, 36 (1997), (3) P. Neuhaus, et al., Liver Transpl. 7, 473 (2001) (Review), (4) B. Nashan, Expert Opin. Investig. Drugs. 11, 1845 (2002) (Review), (5) I. Beuvink, et al., Cell 120, 747 (2005), (6) J.K. Patel & J.A. Kobashigawa, Expert Opin. Pharmacother. 7, 1347 (2006) (Review), (7) P. Smolewski, Anticancer Drugs 17, 487 (2006) (Review), (8) K. Zitzmann, et al., Neuroendocrinology 85, 54 (2007), (9) Z. Zeng, et al., Blood 109, 3509 (2007), (10) R. Bianco, et al., Br. J. Cancer 98, 923 (2008), (11) A.I. Sanchez-Fructuoso, Expert Opin. Drug Metab. Toxicol. 4, 807 (2008) (Review), (12) H.A. Lane, et al., Clin. Cancer Res. 15, 1612 (2009), (13) D. Lebwohl, et al., Ann. N. Y. Acad. Sci. 1291, 14 (2013) (Review), (14) U. Saran, et al., Clin. Sci. 129, 895 (2015) (Review), (15) Morviducci, et al., Diabetes Res. Clin. Pract. (Epub ahead of print) (2018) (Review)
InChi	InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-
Quantity	1 ml, Bulk
cdx-Concentration	1.0 mg/ml in acetonitrile